Phillip G. Febbo, M.D.
Dr, Phillip Febbo is Professor of Medicine and Urology and Leader in the Prostate
Cancer Program at UCSF Helen Diller Family Comprehensive Cancer Center. Dr.
Febbo received his MD degree at the University of California, San Francisco and
completed Internal Medicine Residency at the Brigham and Women' s Hospital in
Boston, Massachusetts. After his fellowship in Medical Oncology at the Dana Farber
Cancer Institute, he was an Attending Physician in the Genitourinary Oncology
Center at the Dana Farber Cancer Institute, Instructor at Harvard Medical School,
and a post-doctoral fellow in Dr. Todd Golub's laboratory at the Dana Farber Cancer
Institute as well as the Whitehead Institute Center for Genomic Research of MIT
(now the Broad Institute). He moved to Duke University's Institute for Genome
Sciences & Policy in 2004 and is currently an Professor of Medicine and Urology at
UCSF. He is also the Principal Investigator with ALLIANCE Translational Research
Program.
The overall objective of Dr. Febbo work is to improve the care of men with prostate
cancer through biological insight and predictive biomarkers. The Febbo Laboratory
uses genomic technologies and defined genetic and/or chemical perturbations to
investigate prostate cancer biology, anticipate response to therapy, and identify
mechanisms of therapeutic resistance. Dr. Febbo has consistently focused on the
incorporation of expression analysis into clinical trials and has worked to create
“learning loops” for prostate cancer clinical trials where the analysis of samples
from one trial informs the design and implementation of subsequent clinical trials.